Neuroendocrine Tumor Treatment Market: Current Analysis and Forecast (2022-2028)

$3999$6999

Emphasis on Products (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, and Others); Indication (Lungs, Pancreas, Gastrointestinal, and Others); End-User (Hospitals, Clinics, and Others); and Region/Country

Pages:

150

Table:

48

Figure:

98

Report ID:

UMHE211404

Geography:

Clear
  Get a Sample
SKU: UMHE211404 Categories: ,
Report Description
Table of content
Research Methodology

Report Description

Neuroendocrine Tumor Treatment Market
Neuroendocrine Tumor Treatment Market

The global neuroendocrine tumor treatment market is expected to grow at a significant rate of around 10% during the forecast period 2022-2028. Over the course of the forecast period, an increase in the number of cases of neuroendocrine tumors (NETs) is anticipated to accelerate the demand for various treatment options. As new diagnostics and therapies are developed, this is a rapidly developing field. The demand NET treatment market is primarily driven by ongoing R&D efforts in detection methods like radiofrequency ablation and Ga-labeled radionucleotide therapies.

For instance, Progenics Pharmaceuticals, Inc.’s PSMA Targeted PET Imaging Agent, for instance, is currently in the clinical trial phase and is anticipated to aid in the treatment of prostate cancer. Another important factor driving the expansion of the NET market is the substantial investment in the field made by cancer research organizations and governments worldwide.

Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., and Advanced Accelerator Applications. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst indication, gastrointestinal category to witness robust CAGR during the forecast period”

Based on type, the market is segmented into lungs, pancreas, gastrointestinal, and others. Among them, the gastrointestinal category is to witness the highest CAGR during the forecast period owing to the more number of patients seen for gastric neuroendocrine growths so there is developing prominence and driving this segment.

Moreover, the pancreas portion is supposed to have consistent development during the following couple of years. The expansion of the market is anticipated to be aided by an increase in R&D expenditures for the creation of novel therapies for pancreatic NETs.Pfizer Inc.’s SUNITINIB is being tested in a phase III clinical trial for the treatment of NETs in the pancreas.

“Amongst end-user, the hospitals to hold a significant share in the market in 2020”

On the basis of drive type, the market is categorized into hospitals, clinics, and others. Among these, the hospitals category to hold a significant share of the market in 2020. This is mainly due to these facilities being used for a lot of diagnostic procedures, a large number of patients treated at hospitals, and the availability of trained professionals. The segment’s expansion is anticipated to be further bolstered by the availability of numerous NET diagnosis options and developed technologies.

“North America to hold a significant share in the market”

For a better understanding of the market adoption of the cardiac monitoring industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific); and the Rest of World. North American region helped the region to obtain a dominating position in the market. This is mainly due to the well-settled healthcare infrastructure, and availability of medical professionals. Furthermore, rising cases of gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and carcinoid tumors in the region are the propel the growth of the market. For instance, carcinoid tumor affects between 3,000 and 30,000 people in the United States, according to data updated in 2021 by the National Center for Advancing Translational Sciences Genetic and Rare Diseases Information Center. These tumors typically originate in the gastrointestinal tract or the lungs. It is anticipated that the market will expand as a result of the widespread incidence of neuroendocrine cancer in the region.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.


Customization Options:

The global neuroendocrine tumor treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation
2.1.Research Process of the Neuroendocrine Tumor Treatment Market
2.2.Research Methodology of the Neuroendocrine Tumor Treatment Market
2.3.Respondent Profile    
3MARKET SYNOPSIS
4EXECUTIVE SUMMARY
5IMPACT OF COVID-19 ON THE NEUROENDOCRINE TUMOR TREATMENT MARKET
6NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE, 2020-2028F
7.1.Somatostatin Analogs (SSAs)
7.2.Targeted Therapy
7.3.Chemotherapy
7.4.Others 
8.1.Lungs 
8.2.Pancreas 
8.3.Gastrointestinal
8.4.Others 
9.1.Hospitals
9.2.Clinics
9.3.Others
10.1.North America  
 10.1.1.U.S.
 10.1.2.Canada
 10.1.3.Rest of North America
10.2.Europe  
 10.2.1.Germany
 10.2.2.U.K.
 10.2.3.France
 10.2.4.Italy
 10.2.5.Spain
 10.2.6.Rest of Europe
10.3.Asia-Pacific 
 10.3.1.China
 10.3.2.Japan
 10.3.3.India
 10.3.4.Rest of Asia-Pacific
10.4.Rest of World 
11.1.Market Drivers
11.2.Market Challenges
11.3.Impact Analysis
12NEUROENDOCRINE TUMOR TREATMENT MARKET OPPORTUNITIES
13NEUROENDOCRINE TUMOR TREATMENT MARKET TRENDS
14.1.Demand Side Analysis
14.2.Supply Side Analysis
15VALUE CHAIN ANALYSIS 
16.1.Competitive Landscape
 16.1.1.Porters Fiver Forces Analysis
17.1.Pfizer Inc. 
17.2.Novartis AG
17.3.Chiasma Inc.
17.4.Ipsen 
17.5.Abbvie Inc.
17.6.Valeant Pharmaceuticals International Inc.
17.7.Jubilant Life Sciences Ltd.
17.8.Teva Pharmaceutical Industries Ltd
17.9.F. Hoffmann-La Roche Ltd
17.10.Advanced Accelerator Applications
18DISCLAIMER

Research Methodology

Research Methodology for the Neuroendocrine Tumor Treatment Market Analysis (2022-2028)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global neuroendocrine tumor treatment market were the three major steps undertaken to create and analyze the adoption of neuroendocrine tumor treatment in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global neuroendocrine tumor treatment market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detail secondary study was conducted to obtain the historical market size of the neuroendocrine tumor treatment market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the neuroendocrine tumor treatment market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as products, indication, and end-user. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the Neuroendocrine Tumor Treatment Market. Further, we conducted factor analysis using dependent and independent variables such as various products, indication, and end-users of neuroendocrine tumor treatment. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the neuroendocrine tumor treatment market sector across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global neuroendocrine tumor treatment market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2028 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

  • The industry’s market size, in terms of revenue (USD) and the adoption rate of the neuroendocrine tumor treatment market across the major markets domestically
  • All percentage shares, splits, and breakdowns of market segments and sub-segments
  • Key players in the global neuroendocrine tumor treatment market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market


Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Neuroendocrine Tumor Treatment Market
Neuroendocrine Tumor Treatment Market

Market Engineering

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global neuroendocrine tumor treatment market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of products, indication, and end-user in the global neuroendocrine tumor treatment market.

The main objective of the Global Neuroendocrine Tumor Treatment Market Study

The current & future market trends of the global neuroendocrine tumor treatment market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of the neuroendocrine tumor treatment market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of products, indication, and end-user.
  • Define and analysis of the regulatory framework for the neuroendocrine tumor treatment industry.
  • Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
  • Analyze the current and forecast market size of the neuroendocrine tumor treatment market for the major region.
  • Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
  • Company profiles of the Neuroendocrine Tumor Treatment Market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Deep dive regional level analysis of the industry

You can also purchase parts of this report. Do you want to check out a section wise
price list?